GLIADEL

This brand name is authorized in United States. It is also authorized in Australia, Brazil, France, Hong Kong SAR China, Ireland, Israel, Japan, Singapore, South Africa, Spain, UK.

Active ingredients

The drug GLIADEL contains one active pharmaceutical ingredient (API):

1	Carmustine UNII U68WG3173Y - CARMUSTINE
	Carmustine is a cell-cycle phase nonspecific antineoplastic agent of the nitrosourea type. As an alkylating agent, it can alkylate reactive sites on nucleoproteins, thus interfering with DNA and RNA synthesis and DNA repair. In addition, carmustine is known to carbamoylate lysine residues on proteins causing irreversible inactivation of enzymes including glutathione reductase.
	Read more about Carmustine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GLIADEL Implant	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01AD01	Carmustine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AD Nitrosoureas
Discover more medicines within L01AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8898H
BR	Câmara de Regulação do Mercado de Medicamentos	542716120003705
ES	Centro de información online de medicamentos de la AEMPS	62745
FR	Base de données publique des médicaments	67758269
GB	Medicines & Healthcare Products Regulatory Agency	75537
HK	Department of Health Drug Office	45555
IL	מִשְׂרַד הַבְּרִיאוּת	6922
JP	医薬品医療機器総合機構	4219700X1020
SG	Health Sciences Authority	13348P
US	FDA, National Drug Code	24338-050
ZA	Health Products Regulatory Authority	32/26/0111